Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-12-13
2005-12-13
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000, C514S045000, C514S653000, C514S826000, C536S027100, C536S027130, C536S027200, C536S027210, C424S045000, C424S046000
Reexamination Certificate
active
06974803
ABSTRACT:
The present invention relates to a combination comprising (a) an adenosine A2areceptor agonist as defined herein and (b) an adrenergic β2 receptor agonist, for simultaneous, sequential or separate administration by the inhaled route in the treatment of an obstructive airways or other inflammatory disease.
REFERENCES:
patent: 6143277 (2000-11-01), Ashurst et al.
patent: 6753322 (2004-06-01), Mantell et al.
patent: 2002/0058641 (2002-05-01), Mantell et al.
patent: WO9967263 (1999-12-01), None
patent: WO0194368 (2001-12-01), None
Berge et al., J. Pharm. Sci, 66, 1-19, 1977.
Sandford et al., Eur. Respir. J., 10, 1380-1391, 1997.
Thomas Giangrasso,Potential for Tolerance, Morbidity, and Mortality Resulting From Regular Use of b2-Adrenergic Agonists in Asthma, Southern Medical Journal, vol. 90, No. 2, pp. 173-179 (Feb. 1997).
Benson Gregg C.
McIntosh III Traviss C.
Mulholland William F.
Pfizer Inc
Richardson Peter C.
LandOfFree
Pharmaceutical combination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical combination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3469734